NASDAQ:NTRB Nutriband 9/3/2024 Earnings Report $4.08 +0.38 (+10.27%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$4.00 -0.08 (-2.06%) As of 05/5/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Nutriband EPS ResultsActual EPS-$0.12Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ANutriband Revenue ResultsActual Revenue$0.44 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ANutriband Announcement DetailsQuarterDate9/3/2024TimeN/AConference Call DateN/AConference Call TimeN/AUpcoming EarningsNutriband's next earnings date is estimated for Friday, May 29, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Nutriband Earnings HeadlinesNutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel PodcastApril 22, 2026 | globenewswire.comNutriband Advances Lead Abuse-Deterrent Fentanyl Patch BrandingApril 7, 2026 | tipranks.comBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered. | Weiss Ratings (Ad)Nutriband Selects Commercial Brand Name for Its Abuse Deterrent Fentanyl PatchMarch 30, 2026 | globenewswire.comNutriband AI Kinesiology Tapes approved for Distribution and Sale in Costa RicaMarch 18, 2026 | finance.yahoo.comNutriband Wins Costa Rica OK for ProductMarch 18, 2026 | baystreet.caSee More Nutriband Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Nutriband? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nutriband and other key companies, straight to your email. Email Address About NutribandNutriband (NASDAQ:NTRB) develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.View Nutriband ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir Drops After a Blowout Q1—What Investors Should KnowShopify’s Valuation Crisis Creates Opportunity in 2026onsemi Stock Dips After Earnings: Why the Dip Is BuyableTSLA: 3 Reasons the Stock Could Hit $400 in MayNebius Breaks Out to All-Time Highs—Here's What's Driving It.3 Reasons Analysts Love DexComMonolithic Power Systems: AI Stock Beat, Raised and Upgraded Post-Earnings Upcoming Earnings AppLovin (5/6/2026)ARM (5/6/2026)DoorDash (5/6/2026)Fortinet (5/6/2026)Marriott International (5/6/2026)Warner Bros. Discovery (5/6/2026)Apollo Global Management (5/6/2026)Cencora (5/6/2026)Cenovus Energy (5/6/2026)CVS Health (5/6/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
